Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Sevelamer is a non-absorbable, polymeric phosphate binder widely utilized in the management of hyperphosphatemia associated with chronic kidney disease (CKD), particularly in patients undergoing dialysis. Chemically, it exists primarily as sevelamer hydrochloride or sevelamer carbonate, which are cross-linked polymers containing amine groups that do not contain calcium or aluminum. The specific molecular formula varies slightly depending on the salt form and polymerization degree, but the core structure relies on a poly(allylamine) backbone cross-linked with epichlorohydrin. Its CAS registry number for sevelamer hydrochloride is 178209-36-4, while sevelamer carbonate carries the number 153986-54-4. Unlike traditional binders like calcium acetate or aluminum hydroxide, Sevelamer offers a distinct safety profile by avoiding systemic absorption and preventing calcium overload or aluminum toxicity.
The primary mechanism of action involves binding dietary phosphate within the gastrointestinal tract through ionic interactions between the positively charged amine groups of the polymer and negatively charged phosphate ions. This complex formation prevents phosphate absorption into the bloodstream, thereby lowering serum phosphorus levels without affecting calcium metabolism. Beyond phosphate control, clinical studies suggest Sevelamer may offer additional cardiovascular benefits, such as reducing low-density lipoprotein cholesterol levels and decreasing vascular calcification progression, making it a preferred choice for long-term renal patients. It is administered orally in tablet or powder form, typically taken with meals to maximize efficacy. By effectively managing mineral and bone disorders common in CKD, Sevelamer plays a critical role in improving patient outcomes and quality of life. Its unique chemical composition ensures it remains inert throughout the digestive system, excreted unchanged in feces, minimizing the risk of adverse drug reactions associated with metal-based binders. Consequently, Sevelamer represents a significant advancement in nephrology therapeutics, providing a robust solution for complex electrolyte imbalances in end-stage renal disease populations worldwide.